Semaglutide Cut Heavy Drinking by Half in a Randomized Trial. The Lancet Published the Proof.

The observational data on GLP-1 receptor agonists and alcohol use disorder has been building for two years. Now there is a randomized controlled trial — the gold standard — and the results are hard to dismiss.

Published in The Lancet, the trial enrolled 108 adults with both alcohol use disorder and comorbid obesity — a clinically common combination, since chronic alcohol use disrupts the same metabolic pathways that regulate appetite and reward. Participants received either once-weekly semaglutide (the active ingredient in Ozempic and Wegovy) or a placebo, alongside standard cognitive behavioral therapy, for 26 weeks. The semaglutide arm showed substantially reduced heavy drinking compared to placebo.

This is the most rigorous evidence yet that GLP-1 receptor agonists — a drug class developed for diabetes and expanded for weight loss — have a meaningful effect on alcohol craving and consumption. The mechanism makes sense, and now the trial data backs it up.

How does it work? GLP-1 receptors (glucagon-like peptide-1 receptors — sensors in the brain and gut that respond to a hormone your body releases after eating) are expressed in the brain’s reward circuitry, including the areas that drive craving for substances. When a GLP-1 agonist like semaglutide activates those receptors, it appears to blunt the reward signal associated with alcohol — reducing the craving, the pleasure of the first drink, and possibly the escalation to heavy use. In plain terms: the drug seems to tell the part of your brain that wants alcohol to quiet down, the same way it tells the part that wants food to quiet down. That is a simplified account — the actual mechanism is still being clarified — but the behavioral result is measurable and real.

An NIH news release accompanying the findings confirmed that adding weekly GLP-1 to CBT further reduces heavy drinking compared to CBT alone — a clinically significant finding because it suggests the effect is incremental rather than redundant with existing behavioral treatment.

Important caveats that any clinical reader needs to know: this is 108 patients, 26 weeks, with a specific comorbidity (obesity). Effect sizes in small, short RCTs sometimes do not replicate in larger, longer trials. Semaglutide is not FDA-approved for alcohol use disorder. Off-label use is possible, but payer coverage is not guaranteed and the monthly cost without coverage can exceed $1,000. A review in The Journal of Clinical Psychiatry notes that head-to-head comparisons with existing AUD medications — naltrexone, acamprosate — have not been done.

For providers seeing patients with both AUD and obesity or type 2 diabetes: if a patient is already on semaglutide or tirzepatide for their metabolic condition, this is a conversation worth having. For patients not already on a GLP-1 agent: the evidence is not yet strong enough for a blanket recommendation, but the trial signal is real and the mechanistic rationale is sound. More trials are coming.

The treatment gap for alcohol use disorder is severe — fewer than 10 percent of people with AUD receive any treatment. If GLP-1 agents hold up in larger trials, they represent a class of medications that many patients are already accessing for other indications, with alcohol benefit as an add-on. That is a different path than developing a novel drug from scratch.

Whether that path runs where the patients are — or only where the insurance covers — is the question.